Compare STBA & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STBA | AMLX |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1995 | 2021 |
| Metric | STBA | AMLX |
|---|---|---|
| Price | $48.65 | $16.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $43.00 | $21.56 |
| AVG Volume (30 Days) | 223.7K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 2.35 | ★ 65.46 |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $51.23 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $34.01 | $5.98 |
| 52 Week High | $48.70 | $18.61 |
| Indicator | STBA | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 69.53 |
| Support Level | $42.52 | $12.17 |
| Resistance Level | $48.70 | $17.22 |
| Average True Range (ATR) | 1.01 | 1.00 |
| MACD | 0.14 | 0.39 |
| Stochastic Oscillator | 94.31 | 95.46 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.